Ajanta Pharma Limited Stock Retained Earnings
| AJANTPHARM | 2,960 14.55 0.49% |
Ajanta Pharma Limited fundamentals help investors to digest information that contributes to Ajanta Pharma's financial success or failures. It also enables traders to predict the movement of Ajanta Stock. The fundamental analysis module provides a way to measure Ajanta Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ajanta Pharma stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | 35.3 B | 37 B |
Ajanta | Retained Earnings |
Ajanta Pharma Limited Company Retained Earnings Analysis
Ajanta Pharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Ajanta Pharma Retained Earnings | 35.25 B |
Most of Ajanta Pharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ajanta Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Ajanta Pharma Limited has a Retained Earnings of 35.25 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The retained earnings for all India stocks is significantly lower than that of the firm.
Ajanta Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ajanta Pharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ajanta Pharma could also be used in its relative valuation, which is a method of valuing Ajanta Pharma by comparing valuation metrics of similar companies.Ajanta Pharma is currently under evaluation in retained earnings category among its peers.
Ajanta Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 362.53 B | ||||
| Shares Outstanding | 124.91 M | ||||
| Shares Owned By Insiders | 66.47 % | ||||
| Shares Owned By Institutions | 22.04 % | ||||
| Price To Book | 10.06 X | ||||
| Price To Sales | 8.23 X | ||||
| Revenue | 42.09 B | ||||
| Gross Profit | 26.92 B | ||||
| EBITDA | 12.57 B | ||||
| Net Income | 8.16 B | ||||
| Total Debt | 352.8 M | ||||
| Book Value Per Share | 293.33 X | ||||
| Cash Flow From Operations | 7.85 B | ||||
| Earnings Per Share | 69.56 X | ||||
| Target Price | 2992.82 | ||||
| Number Of Employees | 8.07 K | ||||
| Beta | 0.1 | ||||
| Market Capitalization | 369.78 B | ||||
| Total Asset | 46.38 B | ||||
| Retained Earnings | 35.25 B | ||||
| Working Capital | 18.35 B | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 46.38 B | ||||
| Last Dividend Paid | 54.0 |
About Ajanta Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ajanta Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ajanta Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ajanta Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ajanta Stock
Ajanta Pharma financial ratios help investors to determine whether Ajanta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ajanta with respect to the benefits of owning Ajanta Pharma security.